Trials / Completed
CompletedNCT01294085
Case Series Study of Biliary Tract Cancer Patients in Japan
Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Kansai Hepatobiliary Oncology Group · Network
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.
Detailed description
Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard therapy for this kind of cancer with the evidence of phase III study compared with gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the patients with recurrent biliary tract cancer after radical resection might differ from those of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be influenced by adjuvant chemotherapy and/or hepatic resection.
Conditions
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-02-01
- Completion
- 2011-08-01
- First posted
- 2011-02-11
- Last updated
- 2011-11-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01294085. Inclusion in this directory is not an endorsement.